Yokley Brian H, Hartman Matthew, Slusher Barbara S
GE Healthcare Life Sciences , Marlborough, Massachusetts 01752, United States.
Academic Drug Discovery Consortium, Baltimore, Maryland 21205, United States.
ACS Chem Neurosci. 2017 Mar 15;8(3):429-431. doi: 10.1021/acschemneuro.7b00040. Epub 2017 Feb 14.
There was a greater than 50% decline in central nervous system (CNS) drug discovery and development programs by major pharmaceutical companies from 2009 to 2014. This decline was paralleled by a rise in the number of university led drug discovery centers, many in the CNS area, and a growth in the number of public-private drug discovery partnerships. Diverse operating models have emerged as the academic drug discovery centers adapt to this changing ecosystem.
从2009年到2014年，大型制药公司的中枢神经系统（CNS）药物研发项目减少了50%以上。与此同时，由大学主导的药物研发中心数量有所增加，其中许多位于中枢神经系统领域，公私合营的药物研发合作关系也在增多。随着学术性药物研发中心适应这一不断变化的生态系统，各种不同的运营模式应运而生。
